12/10/2019 7:00:09 AM
Vertex Says European Commission Granted Approval Of Label
extension For KALYDECO
11/20/2019 5:05:43 AM
Vertex Says French Authorities Approve National Reimbursement Of ORKAMBI
11/13/2019 6:32:56 AM
Vertex Confirms That NHS Wales Accepted Offer For Access To All Licensed Cystic Fibrosis Medicines
10/31/2019 7:25:39 AM
Vertex Announces EMA MAA Validation For VX-445 Tezacaftor And Ivacaftor Triple Combination Regimen
10/30/2019 4:14:43 PM
Vertex Q3 EPS Of $0.22 Vs. $0.50 Last Year
10/24/2019 5:29:39 AM
Vertex Announces Access Deal With NHS England For All
currently Licensed Vertex Cystic Fibrosis Medicines
10/18/2019 8:42:28 AM
Vertex Gets European CHMP Positive Opinion For KALYDECO
7/31/2019 4:22:24 PM
Vertex Pharmaceuticals Inc. (VRTX) Announces $500 Mln Stock Repurchase Plan
7/31/2019 4:21:37 PM
Vertex Pharmaceuticals Inc. (VRTX) Has Raised Its 2019 Revenue Estimate To $3.60 - $3.70 Bln From $3.45 - $3.55 Bln
7/31/2019 4:06:57 PM
Vertex Q2 Non-GAAP EPS $1.26 Vs $0.94 Last Year
7/22/2019 8:19:56 AM
Vertex Submits NDA For Combination Regimen Of VX-445, Tezacaftor, Ivacaftor
7/22/2019 8:06:52 AM
Vertex Submits NDA For Triple Combination Regimen Of VX-445, Tezacaftor And Ivacaftor
5/15/2019 8:35:59 AM
Vertex And Kymera Therapeutics Establish Strategic Collaboration To Develop Targeted Protein Degradation Medicines